Phase III clinical trial for AT-877 (i.v.) in patients with acute ischemic stroke. Placebo-controlled, double-blind add-on therapy to antiplatelet drugs

Phase III clinical trial for AT-877 (i.v.) in patients with acute ischemic stroke. Placebo-controlled, double-blind add-on therapy to antiplatelet drugs - Phase III clinical trial for AT-877 (i.v.) in acute ischemic stroke

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000758

Enrollment

770

Registered

2007-07-02

Start date

2007-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute ischemic stroke (excluding cardioembolic stroke)

Interventions

AT-877 120mg/day or placebo Antiplatelet drug

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) 20 y/o or older upon informed consent (2) Male or female (3) Hospitalization (4) Patients with acute ischemic stroke (excluding cardioembolic stroke) occurring within 48 hrs. of admission

Exclusion criteria

Exclusion criteria: (1) Patients having a history of coronary, renal, hepatic or metabolic disease. Patients exhibiting dysemia (2) Other conditons at the discretion of the investigator

Design outcomes

Primary

Measure	Time frame
Dichotomized mRS score	—

Secondary

Measure	Time frame
Comparison between mRS groups, JSS-M scores	—

Countries

Japan

Contacts

Public ContactToshiya Umeda

Asahi Kasei Pharma Corporation Clinical Development Center

03-3259-5831

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026